Option Chain

Exelixis Inc

EXELNASDAQ · USD

69.57USD+0.86 (+1.26%)

7910

Exelixis Inc (EXEL) Option Chain

Exelixis Inc trades at $69.57, up 1.26%, with an IV Rank of 62.30%. This is average versus the past year, and the company carries a market cap of $16,766M in the Biotechnology industry. On the Nov 20, 2026 chain, the at the money $70.00 strike shows calls at $1.40 / $2.80 and puts at $0.95 / $4.90, both carrying about $2.30 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $70.00 calls, at 510 contracts, and the $70.00 puts, at 5, as of Nov 5, 2026.

Tracking the EXEL option chain helps you see every strike and expiry on Exelixis Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of EXEL options activity at a glance. Use our scanner to monitor the EXEL option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For EXEL stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where EXEL options are being actively traded, and where they are not.

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan.

CALLs									PUTs
Prob. OTM %	Open Interest	Volume	Extrinsic Value	Intrinsic Value	Bid	Ask	Strike	Moneyness %	Bid	Ask	Intrinsic Value	Extrinsic Value	Volume	Open Interest	Prob. OTM %
26.28	2,296	2	0.98	4.57	4.30	6.80	65.00	-5.40	0.55	1.00	0.00	0.78	0	63	73.72
42.56	86	0	0.98	2.07	1.00	5.10	67.50	-1.76	1.00	3.70	0.00	2.35	0	13	57.44
59.62	1,548	510	2.10	0.00	1.40	2.80	70.00	+1.88	0.95	4.90	0.43	2.49	5	46	40.38
74.51	48	13	1.30	0.00	0.60	2.00	72.50	+5.52	2.60	6.60	2.93	1.67	2	5	25.49
85.57	1,472	16	1.70	0.00	—	1.70	75.00	+9.15	4.60	8.60	5.43	1.17	0	0	14.43

As of Nov 5, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

IndustryBiotechnology
SectorHealthcare
IV Rank62.30% Moderate
Market cap (M$)16,766
52 weeks high-6.44%
52 weeks low73.03%
Analyst recommendationBuy
2.47
Target price$61.57
-20.22% below the current stock price
Dividend—
Payout ratio0.00%
Earnings date2026-10-29
P/E20.56
Future P/E16.40
EPS (ttm)3.34
EPS growth next 5 years19.34%

As of Nov 5, 2026

Browse all Option Chain tickers